This site is intended for US health care professionals only.

IMPORTANT SAFETY INFORMATION

This site is intended for US healthcare professionals only.

WARNING: ABUSE AND DEPENDENCE

  • CNS stimulants (amphetamines and methylphenidate-containing products), including Vyvanse, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing and monitor for signs of abuse and dependence while on therapy.
Full Safety Information Below

Vyvanse is indicated for the treatment of moderate to severe binge eating disorder (B.E.D.) in adults. Vyvanse is not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of Vyvanse for the treatment of obesity have not been established.

Diagnosing Adults with Binge Eating Disorder (B.E.D.)

Individuals with B.E.D. must have the following criteria adapted from the DSM-5®¹:

  • Recurrent episodes of binge eating characterized by both of the following:
    • Consuming an abnormally large amount of food in a short period of time compared with what others might eat in the same amount of time under the same or similar circumstances
    • Experiencing a loss of control over eating during the episode
  • Episodes feature at least 3 of the following:
    • Consuming food faster than normal
    • Consuming food until uncomfortably full
    • Consuming large amounts of food when not hungry
    • Consuming food alone due to embarrassment over how much one is eating
    • Feeling disgusted, depressed, or guilty after the binge
  • Overall, there is significant distress about the binge eating.
  • The binge eating occurs, on average, at least once per week for 3 months.
  • The binge eating is not associated with regular compensatory behavior associated with bulimia nervosa and does not occur solely during an episode of bulimia nervosa or anorexia nervosa.

    Diagnosis should be based upon a complete evaluation of the patient that confirms the criteria for B.E.D. established in DSM-5®.

Severity of B.E.D. (based on DSM-5®

  • The minimum level of severity is based on the number of binge eating episodes per week, and may be increased to reflect other symptoms and the degree of functional disability

Mild: 1-3 binge eating episodes per week

Moderate: 4-7 binge eating episodes per week

Severe: 8-13 binge eating episodes per week

Extreme: 14 or more binge eating episodes per week

Shire

DSM-IV® and DSM-5® are registered trademarks of the American Psychiatric Association.

All content of this Web site including text, images, graphics, sound files, and their arrangements, belongs to Shire and is protected by international copyrights laws. All other intellectual property rights are reserved. The content may not be copied for commercial use or distribution nor may these objects be downloaded, modified, or posted to other sites.

This site is intended solely for US residents and is governed solely by US laws and government regulations. Please see our online privacy policy for more information. While Shire US Inc. makes reasonable efforts to include accurate, up-to-date information on the site, Shire US Inc. makes no warranties or representations as to its accuracy. Shire US Inc. assumes no liability for any errors or omissions in the content of the site.

S38425  04/18

You are about to leave vyvansepro.com.

Please be advised that Shire has no control over the content or presentation of the site you are about to view.

Cancel Continue